NEW YORK, May 16 (GenomeWeb News) - Stratagene said today that its recent settlement of a patent dispute with Takara Bio related to PCR enzyme blends has "significantly strengthened its patent portfolio" in this area.
As such, Stratagene said, it now owns a broad
"We believe that there are a number of competitors selling products that are covered under our patent portfolio," Joseph Sorge, president and CEO of Stratagene, said in a statement. "It is our intention to make limited licenses available and recognize resulting licensing revenue."
As GenomeWeb News reported last week, Stratagene and Takara Bio have reached a settlement under which the firms have agreed to pay "reasonable" royalties to each other under certain licensed patents, and each company will be free to independently license its patents to third parties.